alanine has been researched along with Mucositis, Oral in 20 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We retrospectively examined the progression of oral mucositis in 91 patients with breast cancer who received the 5-fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 regimen between September 2007 and August 2008." | 3.80 | [Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer]. ( Abe, M; Bamba, N; Enami, A; Makihara, K; Masaoka, M; Masuda, N; Mizutani, M; Shikata, A; Takada, S; Yamamoto, M; Yamamura, J; Yasojima, H, 2014) |
| "Thirty patients with advanced metastatic colorectal adenocarcinoma were treated with alanosine at a dose of 160 mg/m2 daily for 5 days every 4 weeks." | 3.66 | A phase II study of alanosine in advanced large bowel carcinoma. ( Hahn, RG; Hineman, V; Moertel, CG; Rubin, J; Schutt, AJ, 1983) |
| "In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies." | 2.90 | The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. ( Fujii, M; Konishi, T; Nagamoto, H; Shibasaki, Y; Ueno, T; Yurikusa, T; Zenda, S, 2019) |
| " The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3." | 2.84 | Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. ( Beppu, T; Fujii, M; Fujii, T; Fujimoto, Y; Hasegawa, Y; Hirano, S; Iwae, S; Kojima, H; Matsushima, Y; Matsuura, K; Monden, N; Naka, Y; Nishimori, H; Ogawa, T; Okami, K; Ota, I; Sasaki, K; Tahara, M; Takahashi, S; Tanaka, K; Ueda, S; Ueda, T; Yokota, T, 2017) |
| "60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization." | 2.84 | Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. ( Chaitanya, B; Chhaparwal, Y; Fernandes, D; Pai, KM; Yathiraj, PH, 2017) |
| "Aphthous stomatitis is induced by chemotherapy and radiotherapy." | 2.61 | [Development of Hospital Formulations Based on Medical Need]. ( Hanawa, T; Kawano, Y, 2019) |
| "Oral mucositis is a significant side effect in cancer treatment." | 1.51 | Rebamipide-containing Film Using Chitosan and HPMC for Oral Mucositis Induced by Cancer Chemotherapy. ( Makino, K; Takeuchi, I; Togo, C, 2019) |
| "Irsogladine maleate (IM) is a drug with gastric mucosal protective properties." | 1.48 | [Development of "Patient Friendly Formulations" to Counter the Side Effects of Cancer Chemotherapy]. ( Hanawa, T; Kawano, Y; Satoh, M, 2018) |
| "Oral mucositis is one of the most common side effects induced by cancer therapy, and the prevention or rapid treatment of the symptoms of oral mucositis can improve patients' quality of life and reduce the need for treatment interruption." | 1.48 | Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy. ( Kamiki, Y; Makino, K; Takeuchi, I, 2018) |
| " The pretreatment period, dosing frequency, and dose dependency of rebamipide were examined." | 1.46 | Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats. ( Nakashima, T; Sakurai, K; Uematsu, N, 2017) |
| "Chemotherapy-induced oral mucositis (CIOM) is a severe adverse event resulting from cancer chemotherapy." | 1.42 | [Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis]. ( Nakamura, K; Nakamura, M; Onikubo, T; Shinohara, A, 2015) |
| "L-alanosine (NSC 15353) is a newly developed antitumor antibiotic which acts as an inhibitor of purine intermediary metabolism." | 1.27 | Phase I study of L-alanosine (NSC 15353). ( Goldsmith, MA; Greenspan, EM; Holland, JF; Ohnuma, T; Spigelman, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawano, Y | 3 |
| Hanawa, T | 3 |
| Takeuchi, I | 2 |
| Togo, C | 1 |
| Makino, K | 2 |
| Yokota, T | 1 |
| Ogawa, T | 1 |
| Takahashi, S | 1 |
| Okami, K | 1 |
| Fujii, T | 1 |
| Tanaka, K | 1 |
| Iwae, S | 1 |
| Ota, I | 1 |
| Ueda, T | 1 |
| Monden, N | 1 |
| Matsuura, K | 1 |
| Kojima, H | 1 |
| Ueda, S | 1 |
| Sasaki, K | 1 |
| Fujimoto, Y | 1 |
| Hasegawa, Y | 1 |
| Beppu, T | 1 |
| Nishimori, H | 1 |
| Hirano, S | 1 |
| Naka, Y | 1 |
| Matsushima, Y | 1 |
| Fujii, M | 2 |
| Tahara, M | 1 |
| Ishii, N | 1 |
| Sakai, H | 1 |
| Hayashi, S | 1 |
| Akizuki, N | 1 |
| Komoda, M | 1 |
| Chaitanya, B | 1 |
| Pai, KM | 1 |
| Yathiraj, PH | 1 |
| Fernandes, D | 1 |
| Chhaparwal, Y | 1 |
| Satoh, M | 1 |
| Kamiki, Y | 1 |
| Ueno, T | 1 |
| Zenda, S | 1 |
| Konishi, T | 1 |
| Yurikusa, T | 1 |
| Shibasaki, Y | 1 |
| Nagamoto, H | 1 |
| Nakashima, T | 3 |
| Sako, N | 1 |
| Matsuda, T | 1 |
| Uematsu, N | 3 |
| Sakurai, K | 3 |
| Ishida, T | 1 |
| Enami, A | 1 |
| Masuda, N | 1 |
| Yamamura, J | 1 |
| Mizutani, M | 1 |
| Yasojima, H | 1 |
| Shikata, A | 1 |
| Masaoka, M | 1 |
| Takada, S | 1 |
| Bamba, N | 1 |
| Yamamoto, M | 1 |
| Abe, M | 1 |
| Makihara, K | 1 |
| Shinohara, A | 1 |
| Nakamura, M | 1 |
| Onikubo, T | 1 |
| Nakamura, K | 1 |
| Shibamori, M | 1 |
| Sato, M | 1 |
| Sato, A | 1 |
| Yamamura, Y | 1 |
| Sasabe, H | 1 |
| Umehara, K | 1 |
| Yajima, R | 1 |
| Imaoka, F | 1 |
| Wako, T | 1 |
| Kuroda, Y | 1 |
| Matsumoto, K | 1 |
| Kizu, J | 1 |
| Katayama, S | 1 |
| Kabeya, M | 1 |
| Ina, K | 1 |
| Yuasa, S | 1 |
| Kikuchi, F | 1 |
| Tajiri, C | 1 |
| Kato, T | 1 |
| Hibi, S | 1 |
| Minagawa, Y | 1 |
| Furuta, R | 1 |
| Kayukawa, S | 1 |
| Kataoka, T | 1 |
| Kawai, M | 1 |
| O'Connell, MJ | 2 |
| Rubin, J | 2 |
| Schutt, AJ | 3 |
| Moertel, CG | 2 |
| Kvols, LK | 1 |
| Creagan, ET | 2 |
| Ingle, JN | 1 |
| O'Fallon, JR | 1 |
| Goldsmith, MA | 1 |
| Ohnuma, T | 1 |
| Spigelman, M | 1 |
| Greenspan, EM | 1 |
| Holland, JF | 1 |
| Hineman, V | 1 |
| Hahn, RG | 1 |
| Kovach, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer[NCT02085460] | Phase 2 | 94 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Investigators who had undergone specific training assessed the severity of oral mucositis twice every week. To evaluate the severity of oral mucositis objectively, the clinical findings of the oral mucosa as well as functional disorders and symptomatic aspects were recorded in the Oral Mucositis Assessment Sheet by each investigator. Photographic documentation of the oral mucosa was also submitted by each investigator, 3 days before or 57 days after initiation of chemoradiotherapy, or at the time of withdrawal. The Oral Mucositis Assessment Sheets and photographic documentation were then reviewed by the Oral Mucositis Evaluation Committee to grade the severity of oral mucositis according to the CTCAE 3.0.z (NCT02085460)
Timeframe: 77 days
| Intervention | percentage of participants (Number) |
|---|---|
| 2% Rebamipide Liquid | 29.0 |
| 4% Rebamipide Liquid | 25.0 |
| Placebo | 38.7 |
Day 1 was defined as the start of chemotherapy. (NCT02085460)
Timeframe: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 77
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 15 | Day 22 | Day 29 | Day 36 | Day 43 | Day 50 | Day 57 | Day 64 | Day 71 | Day 77 | |
| 2% Rebamipide Liquid | 31 | 29 | 27 | 25 | 23 | 20 | 18 | 17 | 12 | 11 | 8 | 6 |
| 4% Rebamipide Liquid | 31 | 31 | 30 | 29 | 25 | 20 | 18 | 18 | 16 | 15 | 13 | 11 |
| Placebo | 31 | 30 | 29 | 23 | 23 | 19 | 16 | 15 | 13 | 11 | 8 | 8 |
1 review available for alanine and Mucositis, Oral
| Article | Year |
|---|---|
[Development of Hospital Formulations Based on Medical Need].
Topics: Alanine; Cellulose; Chemical Phenomena; Drug Compounding; Drug-Related Side Effects and Adverse Reac | 2019 |
5 trials available for alanine and Mucositis, Oral
| Article | Year |
|---|---|
Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Topics: Adult; Aged; Alanine; Chemoradiotherapy; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 2017 |
Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis.
Topics: Adult; Aged; Alanine; Case-Control Studies; Chemoradiotherapy; Double-Blind Method; Female; Head and | 2017 |
The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer.
Topics: Aged; Alanine; Chemoradiotherapy; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Male | 2019 |
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo | 2011 |
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials | 1983 |
14 other studies available for alanine and Mucositis, Oral
| Article | Year |
|---|---|
Rebamipide-containing Film Using Chitosan and HPMC for Oral Mucositis Induced by Cancer Chemotherapy.
Topics: Alanine; Antineoplastic Agents; Chitosan; Delayed-Action Preparations; Humans; Hypromellose Derivati | 2019 |
Effects of a Rebamipide Mouthwash on Stomatitis Caused by Cancer Chemotherapy-Evaluation of the Efficacy by Patients Themselves.
Topics: Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Colorectal Neoplasms; Humans; Lung Neoplasm | 2017 |
[Development of "Patient Friendly Formulations" to Counter the Side Effects of Cancer Chemotherapy].
Topics: Administration, Oral; Alanine; Animals; Antineoplastic Agents; Cell Communication; Cyclic AMP; Disea | 2018 |
Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy.
Topics: Alanine; Animals; Anti-Ulcer Agents; Chitosan; Coated Materials, Biocompatible; Drug Liberation; Flu | 2018 |
Novel submicronized rebamipide liquid with moderate viscosity: significant effects on oral mucositis in animal models.
Topics: Administration, Oral; Alanine; Animals; Anti-Ulcer Agents; Cautery; Disease Models, Animal; Drug Car | 2014 |
[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 2014 |
[Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Antioxidants; Dinoprostone; Epoprost | 2015 |
Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice.
Topics: Alanine; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cell Line, Tumor; C | 2015 |
[Basic Studies on the Stability of Flavored Oral Solutions of Rebamipide].
Topics: Administration, Oral; Alanine; Anti-Ulcer Agents; Drug Stability; Humans; Quinolones; Stomatitis | 2015 |
Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats.
Topics: Administration, Oral; Alanine; Animals; Anti-Ulcer Agents; Humans; Male; Quinolones; Rats; Rats, Spr | 2017 |
Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.
Topics: Alanine; Carcinoma, Squamous Cell; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Leukope | 1983 |
Phase I study of L-alanosine (NSC 15353).
Topics: Adult; Aged; Alanine; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Fe | 1983 |
A phase II study of alanosine in advanced large bowel carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alanine; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Evaluatio | 1983 |
A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
Topics: Alanine; Aspartic Acid; Diarrhea; Digestive System Neoplasms; Drug Administration Schedule; Drug Eva | 1983 |